Gilead Sciences Inc. (GILD): Price and Financial Metrics
GET POWR RATINGS... FREE!
GILD POWR Grades
- Value is the dimension where GILD ranks best; there it ranks ahead of 99.29% of US stocks.
- GILD's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
- GILD ranks lowest in Momentum; there it ranks in the 4th percentile.
GILD Stock Summary
- GILD has a market capitalization of $75,897,763,404 -- more than approximately 96.5% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Gilead Sciences Inc is reporting a growth rate of 246.22%; that's higher than 91.47% of US stocks.
- Gilead Sciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 11.51%, greater than the shareholder yield of 85.92% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are KLAC, ADI, EW, NTES, and ON.
- GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to www.gilead.com.
GILD Valuation Summary
- GILD's price/sales ratio is 3.4; this is 10.53% lower than that of the median Healthcare stock.
- GILD's price/sales ratio has moved down 24.1 over the prior 243 months.
- Over the past 243 months, GILD's price/sales ratio has gone down 24.1.
Below are key valuation metrics over time for GILD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
GILD | 2021-08-31 | 3.4 | 4.6 | 17.7 | 15.0 |
GILD | 2021-08-30 | 3.4 | 4.6 | 17.5 | 14.9 |
GILD | 2021-08-27 | 3.4 | 4.5 | 17.3 | 14.8 |
GILD | 2021-08-26 | 3.4 | 4.5 | 17.3 | 14.8 |
GILD | 2021-08-25 | 3.4 | 4.5 | 17.3 | 14.8 |
GILD | 2021-08-24 | 3.4 | 4.6 | 17.5 | 14.9 |
GILD Growth Metrics
- The 4 year net cashflow from operations growth rate now stands at -50.73%.
- Its 5 year net cashflow from operations growth rate is now at -50.73%.
- The 2 year cash and equivalents growth rate now stands at 31.51%.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 27,305 | 11,384 | 6,225 |
2021-09-30 | 27,482 | 10,095 | 7,394 |
2021-06-30 | 26,638 | 9,092 | 5,162 |
2021-03-31 | 25,564 | 9,342 | 301 |
2020-12-31 | 24,689 | 8,168 | 123 |
2020-09-30 | 23,147 | 8,832 | 1,268 |
GILD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
- GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
- ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.
The table below shows GILD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.406 | 0.805 | 0.259 |
2021-06-30 | 0.402 | 0.801 | 0.179 |
2021-03-31 | 0.405 | 0.806 | 0.066 |
2020-12-31 | 0.403 | 0.815 | 0.058 |
2020-09-30 | 0.389 | 0.790 | 0.058 |
2020-06-30 | 0.375 | 0.786 | 0.009 |
GILD Price Target
For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $75.84 | Average Broker Recommendation | 1.7 (Moderate Buy) |
GILD Stock Price Chart Interactive Chart >
GILD Price/Volume Stats
Current price | $62.36 | 52-week high | $74.12 |
Prev. close | $61.81 | 52-week low | $57.17 |
Day low | $61.27 | Volume | 5,207,600 |
Day high | $62.43 | Avg. volume | 9,668,519 |
50-day MA | $62.03 | Dividend yield | 4.68% |
200-day MA | $65.27 | Market Cap | 78.22B |
Gilead Sciences Inc. (GILD) Company Bio
Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).
Latest GILD News From Around the Web
Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.
3 Moonshot Stocks Insiders Are Buying. What Do They Know?Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. |
VIR Q4 Earnings Beat on Higher Revenues From Covid TreatmentVIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients. |
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)By Derek Major |
Tesla Is Just One Reason Why Stocks Are Actually 21% Cheaper NowCurious just how much cheaper the S&P 500 is now due to the sell-off? It's now a nearly a quarter off in about a year's time. |
Is Moderna the Next Gilead or the Next Regeneron?MRNA stock is seen purely as a Covid-19 play. |
GILD Price Returns
1-mo | -0.49% |
3-mo | 4.07% |
6-mo | -11.45% |
1-year | -5.85% |
3-year | 2.45% |
5-year | 6.52% |
YTD | -11.93% |
2021 | 29.95% |
2020 | -6.70% |
2019 | 7.88% |
2018 | -9.92% |
2017 | 2.96% |
GILD Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching GILD
Want to do more research on Gilead Sciences Inc's stock and its price? Try the links below:Gilead Sciences Inc (GILD) Stock Price | Nasdaq
Gilead Sciences Inc (GILD) Stock Quote, History and News - Yahoo Finance
Gilead Sciences Inc (GILD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...